


**Figure 1**

IMP362




Figure 2

IMP413




Figure 3







Figure 4


$\alpha 2b-362$ **Figure 5**

$\alpha 2b-413$ **Figure 6**



	EC50
IFN Std	3.773e-012
IFNa 2b-DDD2	1.591e-011
IFN-IMP362	1.652e-011

Figure 7

**Figure 8**

Therapeutic Efficacy of Several New DNL-Interferon- α 2b
Reagents in Experimental Burkitt's Lymphoma (Daudi).
(s.c. q7dx4)





Figure 9

Survival Curves of Burkitt's Lymphoma (Daudi) Inoculated SCID Mice Administered Intermittent Doses of DNL-IFN- α b (IFN-IMP413)



	Median Survival	Survivors/Total
<u>14,000 Units</u>		
—○— IFN-IMP413 (q7dx4)	>54 days	5/6
—●— IFN-IMP413 (q2wkx4)	>54 days	6/7
--○-- IFN-IMP413 (q3wkx4)	54 days	3/7
<u>14,000 Units</u>		
—□— PEG-INTRON (q7dx4)	36.5 days	1/6
—■— PEG-INTRON (q2wkx4)	28 days	0/7
--□-- PEG-INTRON (q3wkx4)	28 days	0/7
—*— Saline (q7dx4)	23 days	0/6

Figure 10

G-CSF-413






Figure 11

A


h679-FAb-AD2


**+****B**

EPO-DDD2

**↓****C**

EPO-679

**Figure 12**



	EC ₅₀ (U/ml)
EPO-DDD2	0.53
EPO-679	0.24
rhEPO	0.05

Figure 13

EPO-413





Figure 14




IMP-421

Molecular Weight = 2890.50

Ac-C-PEG₃-C(S-Bu)-GQIEYLAKQIVDNAIQAGC(S-Bu)G-NH₂

Figure 15

**Figure 16**